What is Promimic?
Promimic is at the forefront of medical nanotechnology, developing and applying its proprietary HAnano Surface® technology. This bioactive surface modification is designed to significantly improve the performance of implants by promoting enhanced osseointegration and bone growth. With a foundation built on extensive research, validated in over 30 studies and implemented in more than 150,000 clinical cases, Promimic serves a broad spectrum of clients, including dental and orthopedic professionals. The company's technological prowess also extends to applications in biosensors and oncology, positioning it as a versatile innovator in the medtech landscape.
How much funding has Promimic raised?
Promimic has raised a total of $13.2M across 2 funding rounds:
Unspecified
$10M
Private Equity
$3.2M
Unspecified (2011): $10M with participation from Almi Foretags
Private Equity (2016): $3.2M led by Chalmers Ventures
Key Investors in Promimic
Chalmers Ventures
Chalmers Ventures is a leading tech investor and venture builder in the Nordics, specializing in transforming deep tech from lab to market. They support startups by combining venture creation and investment, ensuring a commitment from initial idea to exit. Their focus is on research-based technologies with global commercial potential, providing the necessary capital, expertise, and community for innovators and entrepreneurs. Chalmers Ventures aims to create impactful companies while reinvesting returns to fuel new research and innovation.
Almi Foretags
Almi provides financing in the form of loans and venture capital, as well as support and guidance in business development for small and medium-sized enterprises in Sweden. Their services aim to foster sustainable growth by helping businesses prepare for the future through financial assistance and strategic advice. Almi is state-owned and focuses on ensuring the success and longevity of Swedish companies. They also emphasize the importance of sustainability in business practices to meet the evolving demands of customers and the environment.
What's next for Promimic?
The recent major strategic investment signals a pivotal growth phase for Promimic. This influx of capital is expected to fuel further research and development, potentially expanding the application of their HAnano Surface® technology into new medical fields or enhancing its efficacy in existing ones. The company's focus on improving implant performance and patient outcomes, coupled with its strong scientific validation, positions it for continued expansion and market leadership in the competitive nanotechnology and medical device sectors. Strategic partnerships and further financing rounds may be anticipated as Promimic scales its operations and commercial reach.
See full Promimic company page
